Recent evidence of sustained benefit with exenatide in type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 14, 2006, Pages 2003-2006

  Doggrell, Sheila A ^a  

^a CHARLES DARWIN UNIVERSITY   (Australia)

Author keywords

Exenatide; Metformin; Sulfonylureas; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; EXENDIN 4; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; MEGLITINIDE; METFORMIN; PLACEBO; SULFONYLUREA;

ARTICLE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG POTENTIATION; EPIDEMIC; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; EXPERT TESTIMONY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PEPTIDES; RANDOMIZED CONTROLLED TRIALS; VENOMS; WEIGHT LOSS;

EID: 33749371050     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.14.2003     Document Type: Article

References (13)

1. KORO CE, BOWLIN SJ, BOURGEOIS N, FEDDER DO: Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes. Diabetes Care (2004) 27:17-20.
2. INZUCCHI SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA (2002) 287:360-372.
3. BOJANOWSKA E: Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Med. Sci. Monit. (2005):RA271-RA278.
4. ZANDER M, MADSBAD S, MADSEN JL, HOLST JJ: Effect of 6-week course of glucagon-like pepdde1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet (2002) 359:824-830.
5. GOKE R, FEHMANN HC, LINN T et al.: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. (1993) 268:19650-19655.
6. DEFRONZO RA, RATNER RE, HAN J et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 28:1092-1100.
7. RATNER RE, MAGGS D, NIELSEN LL et al.: Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes. Metab. (2006) 8:419-428.
8. PURNELL JQ, WEYER C: Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat. Endocrinol. (2003) 2:33-47.
9. BUSE JB, HENRY RR, HAN J et al.: Effect of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 27:2628-2635.
10. KENDALL DM, RIDDLE MC, ROSENSTOCK J et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 28:1083-1091.
11. BLONDE L, KLEIN EJ, HAN J et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. (2006) 8:436-447.
12. RIDDLE MC, HENRY RR, POON TH et al.: Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab. Res. Rev. (2006) [Epub ahead of print].
13. DOGGRELL SA: Is exenatide advancing the treatment of type 2 diabetes. Expert Opin. Pharmacother. (2006) 7:109-112.